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OBJECTIVE—We evaluate a potential role of activating transcrip-
tion factor 4 (Atf4) in invertebrate and mammalian metabolism.
RESEARCH DESIGN AND METHODS—With two parallel
approaches—a fat body–speciﬁc green ﬂuorescent protein en-
hancer trap screen in D. melanogaster and expression proﬁling
of developing murine fat tissues—we identiﬁed Atf4 as expressed
in invertebrate and vertebrate metabolic tissues. We assessed the
functional relevance of the evolutionarily conserved expression
by analyzing Atf4 mutant ﬂies and Atf4 mutant mice for possible
metabolic phenotypes.
RESULTS—Flies with insertions at the Atf4 locus have reduced
fat content, increased starvation sensitivity, and lower levels of
circulating carbohydrate. Atf4 null mice are also lean, and they
resist age-related and diet-induced obesity. Atf4 null mice have
increased energy expenditure potentially accounting for the lean
phenotype. Atf4 null mice are hypoglycemic, even before sub-
stantial changes in fat content, indicating that Atf4 regulates
mammalian carbohydrate metabolism. In addition, the Atf4 mu-
tation blunts diet-induced diabetes as well as hyperlipidemia and
hepatosteatosis. Several aspects of the Atf4 mutant phenotype
resemble mice with mutations in components of the target of
rapamycin (TOR) pathway. Consistent with the phenotypic similar-
ities, Atf4 null mice have reduced expression of genes that regulate
intracellular amino acid concentrations and lower intracellular
concentration of amino acids, a key TOR input. Further, Atf4
mutants have reduced S6K activity in liver and adipose tissues.
CONCLUSIONS—Atf4 regulates age-related and diet-induced
obesity as well as glucose homeostasis in mammals and has
conserved metabolic functions in ﬂies. Diabetes 58:2565–2573,
2009
T
he ability to sense nutrient availability and reg-
ulate energy homeostasis is an ancient and fun-
damental process that, when disturbed, leads to
signiﬁcant metabolic derangements (1). Modern
life has provided unparalleled access to food, contributing
to unprecedented proportions of obesity, insulin resis-
tance, and diabetes (1). Epidemiological evidence impli-
cates not only increased fat consumption but also
excess protein intake as causative in the intertwined
epidemics of obesity and diabetes (2). Further, human
trials show that amino acid infusions induce insulin
resistance (3). Two evolutionarily conserved pathways,
target of rapamycin (TOR) and the integrated stress
response (ISR), play central roles in responding to
amino acid availability (4,5).
The mechanisms whereby surplus food consumption
engenders insulin resistance are an area of intense scru-
tiny, and several lines of evidence implicate TOR signaling
as an important contributor (6). TOR signals, which couple
amino acid supplies to translational efﬁciency, are in part
conveyed through ribosomal S6 protein kinase (S6K) and
eukaryotic initiation factor 4E (eIF4E) binding protein 1
(4E-BP1) (4). Recent data indicate that this evolutionarily
conserved cascade links nutrient excess to insulin resis-
tance in ﬂies and mammals (7–10). For example, ﬂies with
mutations in 4E-BP or TOR control fat metabolism, and
the TOR mutants have reduced lipid and glucose levels
(7,8). Similarly, strains of 4E-BP1 mutant mice and S6K
mutant mice are lean and have increased energy expendi-
ture (9,10).
ISR is another highly conserved pathway that is impor-
tant in translational control, nutrient sensing, and glucose
homeostasis (11–13). The ISR is one branch of a signaling
system termed the unfolded protein response (UPR) (12).
Described for its role in handling stress induced by high
demand of protein translation, for example during ana-
bolic states, recent studies illuminate the notion that UPR
has additional roles in metabolic physiology (11–13). For
example, excessive UPR signaling leads to obesity, meta-
bolic dysfunction, and fatty liver (14). Atf4, a bZip tran-
scription factor, is an important component of the ISR (5).
In the liver other bZip factors, C/EBPs, connect the ISR to
several important metabolic functions, such as lipid, glu-
cose, and glycogen biosynthesis, by increasing the expres-
sion of genes such as peroxisome proliferator–activated
receptor  (PPAR) (14). The stress pathway is thought to
have adaptive responses but if prolonged or excess can
lead to maladaptive metabolic changes. For instance, a
variety of animal studies indicate that excess stress, for
example induced by knockouts of components of the UPR
that rectify stress, can lead to obesity and fatty liver (15).
Although the role of Atf4 in metabolic control is yet to be
deﬁned, it is known that Atf4 plays a central function in
handling stress induced by amino acid imbalances (5). In
addition, Atf4 regulates memory formation and is required
for the appropriate development of cell lineages including
blood and bone (16–18). The bone defects can be cor-
rected by feeding the mutant animals a high protein diet,
indicating that the roles of Atf4 in bone formation are
nutritionally linked (19).
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cascades controlling metabolism are conserved among
evolutionarily diverse organisms such as worms, ﬂies, and
mammals (20). To attempt to isolate genes involved in
metabolism, we characterized and compared the molecu-
lar signature of ﬂy and murine developing metabolic
tissues with the premise that conserved genes expressed
in both organisms were plausible candidates. In D. mela-
nogaster, we undertook an enhancer trap screen to isolate
genes expressed in the larval fat body, a central ﬂy
metabolic organ (21), and identiﬁed Atf4. We also found
that Atf4 was expressed in the embryonic day 14.5 (E14.5)
mammalian fat anlagen using a combinatorial transgenic-
transcriptional proﬁling approach. The evolutionarily con-
served expression may have functional relevance because
both Atf4 mutant ﬂies and Atf4 null mice are lean and have
reduced levels of circulating carbohydrate. The Atf4 mu-
tant mice resist diet-induced and age-dependent obesity
and diabetes. Further, the Atf4 mutant mice have in-
creased energy expenditure. Liver and adipose tissues, key
metabolic organs, removed from the Atf4 mutant mice
have reduced expression of genes controlling intracellular
amino acid concentrations. Further, tissues of Atf4 mu-
tants contained lower amino acid levels, thereby support-
ing the idea that changes in amino acid metabolism are
present in vivo. These tissues also have decreased activity
of the TOR signaling pathway, which responds to amino
acid inputs. These data support the notion that Atf4 is a
conserved regulator of metabolism and carbohydrate ho-
meostasis, thus providing a mechanistic link between
nutrients, insulin resistance, and diabetes.
RESEARCH DESIGN AND METHODS
Fly studies. The X-linked enhancer trap P-element, PGawB, was mobilized to
generate new insertions as described previously (22). Individual F1 larvae
were screened for fat body green ﬂuorescent protein (GFP) expression under
a ﬂuorescence-dissecting microscope, and fat body enhancer trap lines were
established by crossing to balancer stocks. Adult fat body tissues were
explanted under dissected microscopy, placed in PBS, and photographed with
differential interference contrast or ﬂuorescence microscopy as described
(20). Insertion sites were identiﬁed by inverse PCR and/or plasmid rescue.
Starvation and triglyceride assays were performed as described (20). For
trehalose quantiﬁcation, 2 l of pooled hemolymph from L3 larvae was
collected, diluted, heat inactivated, and treated with porcine kidney trehalase
(Sigma). Glucose concentration was measured using Inﬁnity Glucose Reagent
(ThermoElectron). For Nile Red staining, whole ﬂies or dissected fat bodies
were ﬁxed in formalin, permeabilized in 0.2% Triton X-100 solution, stained
with Nile Red, and documented under a ﬂuorescence-dissecting scope as
described (20).
Mouse studies. The aP2-GFP mice were generated by placing GFP into the
5.4-kb aP2 enhancer/promoter (23). Multiple transgenic lines were generated
and screened for GFP expression in embryonic and adult fat depots with
ﬂuorescent microscopy. For this study, we selected the transgenic strain with
the highest, most speciﬁc, and most consistent expression of GFP in embry-
onic and adult fat tissues. RNA was extracted from GFP-negative and -positive
cells either after careful dissection or after dissociation and ﬂuorescence-
activated cell sorter (FACS). The Affymetrix microarrays were done by the
University of Texas Southwestern Microarray Core Facility (http://microarray.
swmed.edu). Atf4 heterozygous mice were backcrossed with pure inbred
C57BL/6 mice, housed, and analyzed as described (18,20). Mice were fed
either normal (4% fat, Teklad) or high-fat chow (60% fat, Research Diets). Fat
content was measured using a minispec mq10 NMR Analyzer (Bruker). For
glucose tolerance tests and insulin tolerance tests, 1.25 mg glucose or 0.9 mU
Humulin R (Lilly)/1g body wt was injected intraperitoneally, and blood
glucose levels were measured at the indicated intervals as described (20).
Veterinary care was provided by the Division of Comparative Medicine. All
animals were maintained under the guidelines of the University of Texas
Southwestern Medical Center Animal Care and Use Committee according to
current National Institutes of Health guidelines.
Histological studies. Tissues from Atf4 null and control mice were ﬁxed
with formalin solution, dehydrated with tissue processor (Microm), and
embedded in parafﬁn. Hematoxylin-eosin was used to cut and stain 5- to
8-micron sections. For in situ hybridizations, embryos were collected from
C57BL/6 female mice at E14.5, ﬁxed in formalin, dehydrated, embedded in
parafﬁn, and 5-micron sections hybridized with -
32P-[UTP]–labeled antisense
aP2 or Atf4 probe.
RNA extractions and real-time PCR. Total RNA was extracted using TRIzol
(Invitrogen), DNaseI treated, and reverse transcribed with random hexamers.
Gene expression was analyzed using 7500 Real-Time PCR System (Applied
Biosystems) using SYBR Green Master Mix reagent (Applied Biosystems). The
values for gene expression were normalized by -actin expression. Primer
sequences are available upon request.
Western blotting and antibodies. Immunoblotting was performed accord-
ing to standard procedures. Protein samples were extracted using phospho-
Safe Extraction Reagent (Calbiochem), boiled, and separated on denaturing
polyacrylamide gels (percentage varied from 8–15%) prior to transfer onto
nitrocellulose. The membrane was blocked and incubated with primary
antibodies. Primary antibodies were purchased from the following: -actin
(Sigma), SLC1A4 (Millipore), uncoupling protein (UCP)-1 and AARS (Abcam),
and all other antibodies (Cell Signaling Technology). Subsequently, the
nitrocellulose membranes were washed and incubated with secondary anti-
bodies conjugated with horseradish peroxidase (Jackson Immunoresearch).
Signals are detected with chemiluminescent kits (NEN).
Lipid extraction, gas chromatography, and fatty acid composition.
Floating adipocytes were isolated from control and Atf4 mutants as described
(24). Total lipids were extracted for lipid analysis. Trinonadecanoin and
pentadecanoic acid were used as internal standards for analysis by gas
chromatography. Palmitoleate composition of the triglyceride fraction was
determined by gas chromatography with ﬂame-ionization detection, and the
identity was determined by retention time and compared with the internal
standard for quantiﬁcation.
Measurement of intracellular free amino acid concentration. Protein
concentrations of plasma mixed with 5% trichloroacetic acid and homoge-
nized high-fat diet–fed mouse tissues were determined, and then the samples
were centrifuged. The supernatant was ﬁltered through 0.2 m polytetraﬂuo-
roethylene centrifuge ﬁlter to remove precipitated proteins and tissue debris.
Free amino acid concentrations of the samples were analyzed using a Hitachi
L-8800 amino acid analyzer (25).
Measurement of intracellular cAMP. cAMP concentration was measured
using Cyclic AMP Assay Kit (R&D) according to the manufacturer’s protocol.
Brown adipose tissue (BAT) was homogenized using phosphoSafe Extraction
Reagent (Calbiochem). cAMP concentration of each BAT sample was deter-
mined by comparing with the cAMP standard curve with duplicates of each
protein sample (50 g).
RESULTS
dAtf4 is expressed in the developing and adult D.
melanogaster fat body. To identify genes that might
regulate metabolism, we characterized the molecular sig-
nature of the D. melanogaster larval fat body, a central ﬂy
metabolic organ. We performed a two-component (mini-
mal promoter Gal4; upstream activating sequence–GFP)
enhancer trap insertional screen (22) and isolated 600
lines with fat body GFP expression. This produced a set of
587 genes including many previously reported to be fat
body speciﬁc (e.g., Adh, arg, and vkg). Remarkably, al-
though redundant insertions were quite uncommon, two
of the fat body enhancer trap lines, E8 and G74, had
insertions at the CG8669 locus, encoding the ﬂy homolog
of Atf4 (Fig. 1A) (26). In larvae, E8 expression appeared
relatively speciﬁc to the fat body, whereas G74 also had
ectoskeletal coexpression; both lines also displayed strong
expression in adult metabolic tissues (Fig. 1B).
mAtf4 is expressed in embryonic and adult murine fat
tissues. We also found that Atf4 was expressed in E14.5
murine metabolic tissues in a screen combining ﬂuores-
cent cell–marking techniques, FACS, and microarray tech-
nology. This was based upon the observations that aP2, a
known marker of adult fat depots, had restricted expres-
sion in the E14.5 fat pad (Fig. 1C) (23) and that aP2-GFP
transgenic mice had strong GFP expression in embryonic
fat tissues (Fig. 1D). The latter facilitated isolation of pure
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 and GFP
 cells using dissec-
tions and FACS. We performed a series of Affymetrix
microarray experiments to identify genes upregulated in
GFP
 cells compared with GFP
 cells. We then compared
those genes expressed in the E14.5 fat anlagen with those
identiﬁed in the ﬂy enhancer trap screen; Atf4 was on both
lists. In situ hybridizations and RT-PCR analyses showed
that Atf4 was expressed in embryonic fat depots in the
developing liver, a key metabolic tissue, and also in adult
fat depots (Fig. 1E and F).
Atf4 mutant ﬂies are lean and have reduced circulat-
ing carbohydrate levels. To determine whether the
expression of Atf4 in ﬂy metabolic tissues might have
functional relevance, we examined the phenotype of the
ﬂies with P-element insertions at the Atf4 locus and found
that they had altered metabolism. For example, E8 and
G74 insertion mutant ﬂies had reduced fat content based
upon Nile Red staining of fat body explants, lower triglyc-
eride levels, and increased starvation sensitivity (Fig.
2A–C). These ﬂies also had a trend of reduced circulating
levels of trehalose, the ﬂy glucose equivalent (Fig. 2D).
Atf4 mutant mice are lean and protected from age-
related obesity. The number of Atf4 mutant offspring in
the C57BL/6 (B6) background is reduced (8.9%; 15/168)
compared with the expected Mendelian ratio, but mice
surviving 3 months are healthy and 14% have smaller
body length (control 9.4 	 0.15 cm, n 
 8; mutant 8.1 	
0.22 cm, n 
 6) (27). To evaluate a potential role of Atf4 in
mammalian metabolism, we analyzed young adult cohorts
(aged 3 months) of Atf4 null and control siblings fed
normal chow diet. Because aging is associated with in-
creased insulin resistance and obesity (28,29), we also
studied older mice (aged 12 months). Based upon
appearance, nuclear magnetic resonance fat content
analyses, and examination of adipose depots, the young
adult Atf4 mutants had modestly reduced fat mass
compared with controls, and this effect substantially
increased with age (Fig. 3A–E), indicating that the Atf4
mutants resist age-associated obesity. However, kidney
and heart weights, normalized to lean body mass, ap-
proximated those of controls (Fig. 3F, supplemental
Table S1 in the online appendix, available at http://
diabetes.diabetesjournals.org/content/early/2009/08/13/
db09-0335/suppl/DC1). At young ages, Atf4-deﬁcient adi-
pocytes were of similar size to or in some cases even
larger than control adipocytes. However, they had a
blunted hypertrophic response to age-associated obe-
sity (Fig. 3G).
Atf4 mutant mice resist diet-induced obesity. To ex-
amine the potential role that Atf4 may play in diet-induced
obesity, we provided a high-fat diet to control and Atf4
mutant littermates. During the 16 weeks of high-fat diet,
we followed the mice with weekly weights, normalizing
them to starting weight, and found that Atf4 mutants had
a signiﬁcantly blunted response to high-fat diet (Fig. 4A).
This resistance to diet-induced weight gain was accompa-
nied by a marked decrease in fat accumulation as deter-
mined by nuclear magnetic resonance analyses as well as
by gross observation and weights of fat depot explants
(Fig. 4B–E). However, the weights of other organs were
not affected (data not shown). The differences in fat
content are apparent in histological sections, which show
that although control mice have signiﬁcant fat, Atf4 null
mice have a paucity of such deposition (Fig. 4F). In
addition, the adipocytes are substantially smaller than
those observed in controls (Fig. 4F). Fatty liver, a leading
cause of liver disease, is a manifestation of metabolic
dysfunction that can be elicited by high-fat diet (30).
Consistent with that, we found that high-fat diet led to
FIG. 1. Atf4 is expressed in ﬂy and mammalian metabolic tissues. A:
Schematic diagram of E8 and G74 insertions at the CG8669 locus
encoding the ﬂy Atf4 homolog (dAtf4). B: The E8 and G74 enhancer
trap lines express upstream activating sequence–GFP in the larval
(top) and adult (bottom) fat body. Lower right panels show differential
interference contrast image of the adult fat body explants. C: aP2 in
situ hybridization on a parasagittal section of an E14.5 mouse embryo.
D: Dorsal view of an E14.5 aP2-GFP transgenic embryo viewed with
ﬂuorescence microscopy. E: Atf4 in situ hybridization on E14.5 mouse
embryo. The arrow highlights Atf4 expression in the E14.5 fat pad, and
the arrowhead identiﬁes liver expression. F: RT-PCR of cDNA derived
from the embryonic fat tissue (EFT) of wild-type (left lane) and Atf4
null (right lane) mice and adult inguinal wild-type WAT (IWAT, middle
lane) mice. HPRT (hypoxanthine phosphoribosyl transferase) serves
as a loading control.
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FIG. 2. Atf4 regulates ﬂy metabolism. A: Photo of Nile Red–stained (fat
stains red) E8 dAtf4 insertional mutant (Mut) and control (Cont)
larval fat body. B: Triglyceride levels of G74 dAtf4 insertional mutants
and controls (n > 40). C: Day 5 starvation survival of G74 dAtf4
insertional mutants and controls (n > 40). D: Trehalose levels of E8
larvae of dAtf4 insertional mutants and controls (n > 40). Error bars
indicate SEM. Statistical signiﬁcance was assessed by two-tailed Stu-
dent t test. *P < 0.05.
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(Fig. 4G, H). In contrast, Atf4 mutants were resistant to
this pathology (Fig. 4G and H).
Atf4 mutant mice are hypoglycemic. Next we examined
control and Atf4 mutant siblings for aspects of glucose
homeostasis and found that Atf4 regulated murine carbo-
hydrate metabolism. For example, Atf4 mutants had lower
random and fasting glucose levels, and glucose tolerance
tests showed that normal chow–fed Atf4 null mice had
improved glucose metabolism (Fig. 5A–C). Even at the
young ages, the Atf4 mutant cohorts displayed glucose
levels and glucose tolerance test results that were reduced
compared with controls (Fig. 5B) and seemingly out of
proportion to the relatively modest changes in fat content
observed at these ages (Fig. 3C). This may indicate that
Atf4 has direct functions in glucose metabolism that are
independent of the degree of fat reduction. In support of
that notion, we found that insulin levels in normal chow–
fed Atf4 mutants approximated control levels (Fig. 5D).
This normal insulin level, in the setting of lowered blood
glucose, indicates relative insulin excess and may be
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diet. B: Photograph of 1-year-old normal chow–fed control and Atf4 null
siblings. C: Nuclear magnetic resonance body fat analyses of 3-month-
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control and Atf4 null mice (n > 6). D: Photograph of representative
mesenteric WAT (MWAT) and inguinal WAT (IWAT) depots from
12-month-old normal chow–fed control and Atf4 null littermates. E:
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perigonadal WAT (GWAT), and MWAT depots of 3-month-old (Y) and
12-month-old (O) Atf4 null siblings (n > 6). F: Average weight normal-
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1-year-old (old) control and Atf4 null mice (n > 6). G: Histology of
IWAT of 3-month-old and 1-year-old normal chow–fed control and Atf4
mutant siblings (bar  50 m). Error bars indicate SEM. Statistical
signiﬁcance was assessed by two-tailed Student t test or repeated-
measures ANOVA followed by Bonferroni post tests (A). *P < 0.05;
**P < 0.01.
Cont
B A
Cont
Null
Cont
Null
Cont Null
D
F
S
W
A
T
I
W
A
T
0
10
20
30
40
50
60
Cont Null
**
%
 
B
o
d
y
 
F
a
t
0
20
40
60
80
100
120
140 Cont
Null
Weeks
W
e
i
g
h
t
 
i
n
c
r
e
a
s
e
 
(
%
)
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
C
1 4 7 1 01 31 6
0
2
4
6
8
10
12
14 Cont
Null
IWAT GWAT MWAT
*
*
*
*
*
*
%
 
o
f
 
L
e
a
n
 
m
a
s
s
0.0
0.5
1.0
1.5
2.0
2.5
Null Cont
L
i
v
e
r
 
(
m
g
)
,
 
X
1
0
3 G H
*
E
Null
Cont
IWAT GWAT
RWAT
Null
Null Cont
FIG. 4. Atf4 mutant mice are lean and resist age-associated and
diet-induced obesity. A: Serial weights of control (Cont) and Atf4 null
siblings on high-fat diet. B: Photograph of representative control and
Atf4 mutant littermates after 16 weeks of high-fat diet. C: Nuclear
magnetic resonance body fat analyses of 6-month-old high-fat diet–fed
control and Atf4 null mice (n > 6). D: Photograph of representative
perigonadal WAT (GWAT), perirenal (RWAT), and inguinal WAT
(IWAT) depots from high-fat diet–fed control and Atf4 null littermates.
E: Average weights of IWAT, GWAT, and MWAT depots of 6-month-old
high-fat diet control and Atf4 null siblings (n > 6). F: Histology of skin
WAT (SWAT) and IWAT of high-fat diet control and Atf4 mutant
siblings (bar  50 m). G: Liver weights of high-fat diet control and
Atf4 null siblings (n  8). H: Representative liver histology of high-fat
diet control and Atf4 nulls (bar  50 m). Error bars indicate SEM.
Statistical signiﬁcance was assessed by two-tailed Student t test or
repeated-measures ANOVA followed by Bonferroni post tests (A). *P <
0.05; **P < 0.01.
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-cell apoptosis, proliferation, and insulin secretion
(31–33).
The Atf4 mutation also ameliorated high-fat diet–
induced hyperglycemia (Fig. 5E). However, in this setting
insulin levels were signiﬁcantly lower than those for
controls (Fig. 5F), pointing to roles of Atf4 in metabolism
that are independent of the pancreas and potentially
related to the lean phenotype described above. An insulin
tolerance test indicated that the Atf4 mutant mice were
insulin sensitive (Fig. 5G). Diet-induced and age-related
obesity can provoke hyperlipidemia (1). The Atf4 mutation
appeared to ameliorate this adverse consequence as the
high-fat diet Atf4 null mice and the 12-month-old normal
chow–fed mutants had improved lipid proﬁles compared
with those for controls (Fig. 5H and I). Recent evidence
indicates that the adipose-generated lipid palmitoleate is a
lipokine that regulates glucose homeostasis (34). This
does not appear to be the mechanism whereby Atf4
impacts metabolism because control and Atf4 mutant fat
depots had equivalent levels of this fatty acid (Fig. 5J).
Atf4 mutant mice have increased energy expenditure.
To attempt to identify the basis of the lean phenotype, we
examined eating behavior, activity, and metabolic rate
comparing Atf4 null and control siblings on either normal
chow or high-fat diet. Food intake was equivalent in the
Atf4 mutants and controls (Fig. 6A). The leanness was not
due to increased activity because X-Y movement (walking)
was equivalent in the two groups and Z-axis (rearing)
activity was reduced by Atf4 deﬁciency (Fig. 6B). Atf4 null
mice did have increased energy expenditure, displaying a
higher rate (15% increase) of oxygen consumption (VO2)
in both light and dark phases that was accentuated by
high-fat diet (30% increase) (Fig. 6C and D). Because
adipose tissue, reduced in Atf4 mutants, and muscle have
differential contributions to whole-body VO2, we repeated
the metabolic chamber analyses on additional cohorts of
mice and in these cases with normalized energy expendi-
ture using lean body mass. Again, Atf4 mutant mice had
elevated energy expenditure (Fig. 6E and G). We also
plotted the absolute energy expenditure (a per mouse
analysis, plotting lean mass vs. VO2) of control and Atf4
mutants, and the slopes are illustrated in supplemental
Fig. S1 in the online appendix. Another indication of
altered metabolism is the observation that Atf4 mutants
had a substantially lower respiratory quotient (RQ, VCO2/
VO2), a measure of the proportionate rates of substrate
utilization, indicating higher fat oxidation (Fig. 6F). Core
body temperature is an additional measure of energy
expenditure. Consistent with the other metabolic studies,
we found that Atf4 mutant mice had elevated core body
temperature (Fig. 6H). Given the starvation sensitivity
observed in the Atf4 mutant ﬂies (Fig. 2C), we also
measured respiratory quotient and VO2 during the fed-to-
fasted transition. Initially the respiratory quotients and
VO2s became similar, but with a sustained fast the mutant
animal VO2 dropped precipitously and the mutants be-
come acutely ill. This indicates a potential defect in
starvation resistance, reminiscent of ﬂy starvation intoler-
ance (Figs. 2C,6 F, and 6G). Next we investigated potential
energy expenditure defects molecularly. Levels of per-
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UCP-1, and/or cAMP often reﬂect metabolic rate. We
determined their expression or concentration in adipose
tissues. First, we examined cAMP levels in BAT, a major
source of thermogenesis. We observed a trend toward
increased cAMP concentrations in Atf4 mutant mice (Fig.
6I), possibly reﬂecting increased metabolic activity. Next,
we quantiﬁed mRNA levels in BAT and white adipose
tissue (WAT) using qPCR. Expression of some genes
involved in mitochondrial biogenesis and energy expendi-
ture (e.g., PGC1- and UCP-1) was slightly increased in
Atf4 mutant BAT and WAT (Fig. 6J). We then examined
the levels of these two proteins using Western blots. We
found that PGC1-, a key transcriptional regulator of
oxidative capacity, was modestly increased in both tissues
with a greater increase in WAT. Notably, the Western blots
revealed a marked increased (10-fold) in UCP-1 protein
levels (often thought of as a marker of BAT) in Atf4
mutant WATs (Fig. 6K). Consistent with that observation,
we found that Atf4 mutant mice contained multilocular
adipocytes, characteristics of BAT in WAT depots (Fig. 6L).
Atf4 mutant mice have reduced TOR activity. Several
lines of evidence indicate that Atf4 regulates intracellular
amino acid metabolism (5,25). Notably, high intake of
amino acids leads to both adiposity and insulin resistance
(2,3). In cellular assays, Atf4 siRNA reduces intracellular
concentrations of amino acids (25). Because reduced
amino acid availability could account for various aspects
of the Atf4 mutant phenotype (35), we assessed expres-
sion of genes important in intracellular amino acid con-
centrations in control and Atf4 mutant mouse embryonic
ﬁbroblasts (MEFs) as well as adipose depots and livers
because these two tissues are metabolically relevant and
are affected by Atf4 deﬁciency. Based upon qPCR, we
detected signiﬁcantly reduced levels of genes regulating
amino acid metabolism, and transport was in Atf4 mutant
MEFs (Fig. 7A and B). We also measured protein levels of
some of the salient genes. We found that alanyl-tRNA
synthetase was signiﬁcantly reduced, whereas solute car-
rier family 1 member 4 levels were equivalent. Both liver
and adipose tissues from Atf4 mutant mice also showed
the same trends as those detected in the MEFs (Fig. 7C
and D). We extended the data by directly quantifying
amino acid concentrations in plasma, liver, and adipose
depots of control and Atf4 mutant siblings (Fig. 7E and
supplemental Fig. S2 in the online appendix). Although
plasma amino acid levels were comparable, the Atf4
mutant tissues displayed a trend toward reduced concen-
trations of amino acids. Several of the metabolic charac-
teristics observed in the Atf4-deﬁcient ﬂies and mice
mirror phenotypes observed when components of the TOR
pathway are mutated in those organisms (7–10). These
phenotypic similarities coupled with the Atf4-dependent
regulation of amino acid availability, a key TOR input
(5,36), prompted us to examine metabolic tissues of Atf4
mutants and control siblings for TOR activity. Therefore,
we assessed the phosphorylation of S6K, a key TOR target,
in liver and adipose tissues removed from Atf4 mutants
and control siblings. We found that S6K phosphorylation
was reduced in Atf4 mutant liver and adipose tissues (Fig.
7F). We observed a similar reduction in the levels of
phosphorylation of S6, an S6K target (Fig. 7F). To examine
the possibility that the Atf4 mutation might lead to a state
of energy depletion and consequent altered TOR activity,
we analyzed the activity of AMP-activated protein kinase,
a central regulator and sensor of intracellular energy
balance and changes in ATP levels (37). However, the
levels of AMP-activated protein kinase phosphorylation in
the activation loop were similar in control and Atf4 mutant
tissues (Supplemental Fig. S3 in the online appendix).
DISCUSSION
Energy homeostasis is maintained by a dynamic interac-
tion between several organ systems that coordinate food
intake, energy stores, metabolic demands, and energy
expenditure (38,39). The understanding of metabolism has
fundamental and clinical importance, so efforts directed
toward characterization of molecules controlling energy
homeostasis and metabolism have therapeutic potential.
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scription factor, regulates several aspects of mammalian
metabolism, including fat storage, energy expenditure, and
glycemic control. Some of these functional attributes may
be conserved because Atf4 is expressed in the Drosophila
fat body, a major ﬂy metabolic organ, and ﬂies with
insertions into the dAtf4 locus are lean and have reduced
circulating carbohydrate levels.
Modernity has produced a marked increase in dietary
protein intake, which in turn has epidemiological and
experimental links to the current explosion of obesity and
diabetes. Protein synthetic overload is often sensed in the
endoplasmic reticulum, an organelle in which newly trans-
lated proteins are sorted and modiﬁed (13). The surplus in
endoplasmic reticulum handling of proteins triggers the
UPR, a central mechanism designed to handle endoplas-
mic reticulum stress (40). Accumulated evidence indicates
that endoplasmic reticulum stress pathways couple obe-
sity to metabolic dysfunctions such as diabetes (41,42).
The UPR is composed of several different limbs; each
handles different aspects of the stress response (11–13).
One arm of the UPR increases the availability of endoplas-
mic reticulum chaperons, which in turn remodel misfolded
proteins into the appropriate structure. Another arm of the
UPR, ISR, reduces endoplasmic reticulum workload by
inhibiting bulk protein translation. A few mRNAs, such as
those encoding the bZIP class transcription factors Atf4,
C/EBP, and C/EBP (14), respond to the ISR signal
paradoxically, thereby increasing their translation. In turn,
these proteins affect transcriptional programs that in-
crease the ability of the cell to handle stress (12,42).
Recent studies have illuminated a key role that these
proteins and the ISR play in metabolism. For example, the
ISR regulates pancreatic -cell survival, proliferation, and
insulin secretion, and the normal chow–fed insulin levels
observed in the Atf4 mutants resonate with previous
descriptions (33,43).
That ISR contributes to negative outcomes produced by
overindulgence may have evolutionary connections all the
way to yeast (12). The TOR pathway also regulates inver-
tebrate and vertebrate metabolism (7–10). Here, we
showed that tissues derived from Atf4 mutant mice have
reduced TOR signaling, reduced expression of genes im-
portant in the intracellular concentration of amino acids,
and thereby, reduced concentration of amino acids, a
major TOR input. These results underscore a potential
intimate relationship between Atf4 function, ISR, TOR
pathway, and metabolism that could be therapeutically
exploited.
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